Patient‐reported outcomes of blue‐light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study

To evaluate blue‐light flexible cystoscopy (BLFC) with hexaminolevulinate in the office surveillance of patients with non‐muscle‐invasive bladder cancer with a high risk of recurrence by assessing its impact on pain, anxiety, subjective value of the test and patient willingness to pay.

[1]  Paul K J Han,et al.  Distress Due to Prognostic Uncertainty in Palliative Care: Frequency, Distribution, and Outcomes among Hospitalized Patients with Advanced Cancer. , 2018, Journal of palliative medicine.

[2]  Sanjay G. Patel,et al.  Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study , 2017, The Journal of urology.

[3]  S. Selph,et al.  Comparative Effectiveness of Fluorescent Versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta‐Analysis , 2017, The Journal of urology.

[4]  John D Seigne,et al.  Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. , 2016, The Journal of urology.

[5]  D. Cella,et al.  Clinical validity of PROMIS Depression, Anxiety, and Anger across diverse clinical samples. , 2016, Journal of clinical epidemiology.

[6]  L. Price,et al.  Patient-Reported Outcomes Measurement Information System (PROMIS) instruments among individuals with symptomatic knee osteoarthritis: a cross-sectional study of floor/ceiling effects and construct validity , 2015, BMC Musculoskeletal Disorders.

[7]  Jingwei Wu,et al.  Operating characteristics of PROMIS four-item depression and anxiety scales in primary care patients with chronic pain. , 2014, Pain medicine.

[8]  R. Gershon,et al.  Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment , 2014, Quality of Life Research.

[9]  Grace Chen,et al.  Patients with chronic pain. , 2013, The Medical clinics of North America.

[10]  Dieter Jocham,et al.  Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. , 2013, European urology.

[11]  E. Jonasch,et al.  Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. , 2013, European urology.

[12]  Amy P Abernethy,et al.  Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Sargent,et al.  Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Sargent,et al.  Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Stone,et al.  Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Edge,et al.  AJCC Cancer Staging Handbook, 6th edition , 2002 .